RICERCA
AUTORI
RIVISTE
Sfoglia per AUTORE
BOMBEN R
Collezione AOU Novara
Items : 12
Efficacy of front-line ibrutinib versus fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: A retrospective multicenter "Real-World" study. in American journal of hematology / Am J Hematol. 2023 Feb;98(2):E24-E27. doi: 10.1002/ajh.26779. Epub 2022 Nov 25.
2023
AO Cuneo
AOU Città della Salute di Torino
AO Alessandria
AOU Novara
Levi S; Trentin L; Foà R; Cuneo A; Herishanu Y; Gentile M; Perry C; Gattei V; Gaidano G; Rossi D; Neri A; Olivieri J; Bomben R; Zucchetto A; Visentin A; Loseto G; Pietrasanta D; Chiarenza A; Braester A; Murru R; Aviv A; Varettoni M; Coscia M; Tadmor T; Shvidel L; Sportoletti P; Laurenti L; Reda G; Ruchlemer R; et alii...
Quality Assessment for PCR-based Minimal Residual Disease in Lymphoma: 10 Years of Cross-laboratory Standardization Process Within the Fondazione Italiana Linfomi MRD Network. in HemaSphere / Hemasphere. 2021 Sep 6;5(10):e639. doi: 10.1097/HS9.0000000000000639. eCollection 2021 Oct.
2021
AOU Città della Salute di Torino
AOU Novara
Drandi D; Ferrero S; Ladetto M; Gaidano G; Del Giudice I; Galimberti S; Gattei V; Agostinelli C; Delfau-Larue MH; García-Sanz R; Pott C; Alessandria B; Degan M; Bomben R; Mannu C; Gazzola A; Cavalli M; De Novi LA; Ciabatti E; Grassi S; Della Starza I; Ferrante M; Genuardi E; Mantoan B;
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study. in American journal of hematology / Am J Hematol. 2021 May 1;96(5):E168-E171. doi: 10.1002/ajh.26127. Epub 2021 Feb 24.
2021
AO Cuneo
AOU Città della Salute di Torino
AO Alessandria
AOU Novara
Gentile M; Gattei V; Foà R; Ferrarini M; Polliack A; Gaidano G; Trentin L; Cuneo A; Fronza G; Cutrona G; Rossi D; Di Raimondo F; Neri A; Bomben R; Biagi A; Del Giudice I; Angeletti I; Galimberti S; Rago A; Caracciolo D; Cassin R; D'Arrigo G; Mendicino F; Botta C; Martino EA; Vigna E; Zucchetto A; Rossi FM; Scortechini I; et alii...
Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study. in Leukemia / Leukemia. 2021 Jan;35(1):235-238. doi: 10.1038/s41375-020-0833-x. Epub 2020 Apr 14.
2021
AO Cuneo
AOU Città della Salute di Torino
AO Alessandria
AOU Novara
Sportoletti P; Laurenti L; Gattei V; Gaidano G; Polliack A; Foà R; Rossi D; Cuneo A; Di Raimondo F; Rigolin GM; Bomben R; Biagi A; Del Giudice I; Angeletti I; Rago A; Arrigo G; Vigna E; Botta C; Tripepi G; Fraticelli V; Zucchetto A; Scortechini I; Loseto G; Consoli U; Rossi FM; Pietrasanta D; Murru R; Chiarenza A; Condoluci A; et alii...
TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases. in American journal of hematology / Am J Hematol. 2021 Aug 1;96(8):E306-E310. doi: 10.1002/ajh.26235. Epub 2021 May 25.
2021
AO Cuneo
AOU Città della Salute di Torino
AO Alessandria
AOU Novara
Gentile M; Gattei V; Ferrarini M; Foà R; Polliack A; Trentin L; Cuneo A; Gaidano G; Di Raimondo F; Rossi D; Olivieri J; Jaksic O; Bomben R; Neri A; Fronza G; Rago A; Angeletti I; Cutrona G; Del Giudice I; Biagi A; Galimberti S; D'Arrigo G; Al-Janazreh H; Martino EA; Vigna E; Tripepi G; Zucchetto A; Rossi FM; Recchia AG; et alii...
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials. in American journal of hematology / Am J Hematol. 2021 Aug 1;96(8):E269-E272. doi: 10.1002/ajh.26201. Epub 2021 May 3.
2021
AO Cuneo
AOU Città della Salute di Torino
AO Alessandria
AOU Novara
D Arrigo G; Murru R; Gentile M; Gattei V; Polliack A; Trentin L; Gaidano G; Di Raimondo F; Cuneo A; Cutrona G; Rossi D; Menichini P; Olivieri J; Fronza G; Monti P; Del Giudice I; Bomben R; Neri A; Angeletti I; Biagi A; Rago A; Martino EA; Cassin R; Galimberti S; Foà R; Ferrarini M; Scortechini I; Rossi FM; Zucchetto A; et alii...
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases. in European journal of haematology / Eur J Haematol. 2021 Apr;106(4):493-499. doi: 10.1111/ejh.13573. Epub 2021 Jan 28.
2021
AO Cuneo
AOU Città della Salute di Torino
AO Alessandria
AOU Novara
Gentile M; Gattei V; Ferrarini M; Foà R; Trentin L; Polliack A; Gaidano G; Cuneo A; Di Raimondo F; Rossi D; Jaksic O; Monti P; Cutrona G; Bomben R; Neri A; Fronza G; Menichini P; Biagi A; Del Giudice I; Angeletti I; Rago A; Galimberti S; Cassin R; D'Arrigo G; Mendicino F; Martino EA; Vigna E; Al-Janazreh H; Zucchetto A; et alii...
Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib-rituximab. in Blood cancer journal / Blood Cancer J. 2020 Sep 16;10(9):92. doi: 10.1038/s41408-020-00358-3.
2020
AOU Città della Salute di Torino
AO Cuneo
AO Alessandria
AOU Novara
Gattei V; Morabito F; Ferrarini M; Gaidano G; Cuneo A; Foà R; Trentin L; Fronza G; Cutrona G; Di Raimondo F; Angeletti I; Bomben R; Neri A; D'Arrigo G; Tripepi G; Vitale C; Al-Janazreh H; Rossi FM; Zucchetto A; Scortechini I; Consoli U; Loseto G; Pietrasanta D; Bossio S; Moia R; Recchia AG; Lucia E; Mendicino F; Vigna E; et alii...
HIF-1? is over-expressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia. in Haematologica / Haematologica. 2020 Apr;105(4):1042-1054. doi: 10.3324/haematol.2019.217430. Epub 2019 Jul 9.
2020
ASL Asti
AO Cuneo
AOU Città della Salute di Torino
ASL Vercelli
AOU Novara
Boccadoro M; Gattei V; Foà R; Massaia M; Gaidano G; Zenz T; Bernardi R; Mauro FR; Laurenti L; Del Poeta G; Kodipad AA; Omedè P; Magliulo D; Rossi D; Marchetti M; Bonello L; Pozzato G; Bo MD; Kopecka J; Bomben R; Salvetti C; Riganti C; Todaro M; Vitale C; Griggio V; Coscia M;
Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia. in Haematologica / Haematologica. 2020 Jan 31;105(2):448-456. doi: 10.3324/haematol.2019.219550. Print 2020.
2020
AOU Città della Salute di Torino
AOU Novara
Cuneo A; Follenzi A; Poeta GD; Bertoni F; Lawless S; Thornton P; Mills K; Donaldson D; Weir P; Motta M; Laurenti L; Tedeschi A; Perbellini O; Coscia M; Marasca R; Rigolin GM; Chiarenza A; Visco C; Rossi FM; Bomben R; Cortelezzi A; Zaja F; Forconi F; Mauro FR; Giudice ID; Peroni D; Kodipad AA; Jabangwe C; Sagiraju S; et alii...
Biallelic BIRC3 inactivation in chronic lymphocytic leukaemia patients with 11q deletion identifies a subgroup with very aggressive disease. in British journal of haematology / Br J Haematol. 2019 Apr;185(1):156-159. doi: 10.1111/bjh.15405. Epub 2018 May 22.
2019
AOU Novara
Raponi S; Del Giudice I; Ilari C; Cafforio L; Messina M; Cappelli LV; Bonina S; Piciocchi A; Marinelli M; Peragine N; Mariglia P; Mauro FR; Rigolin GM; Rossi F; Bomben R; Dal Bo M; Del Poeta G; Diop F; Favini C; Rossi D; Gaidano G; Cuneo A; Gattei V; Guarini A; Foá R;
A B-cell receptor-related gene signature predicts survival in mantle cell lymphoma: results from the Fondazione Italiana Linfomi MCL-0208 trial. in Haematologica / Haematologica. 2018 May;103(5):849-856. doi: 10.3324/haematol.2017.184325. Epub 2018 Feb 22.
2018
AOU Città della Salute di Torino
AO Alessandria
AOU Novara
Ladetto M; Cortelazzo S; Gaidano G; Wiestner A; Piccin A; Liu D; Luminari S; Arcaini L; Rigacci L; Rusconi C; Vitolo U; Omedè P; Zamò A; Evangelista A; Carella AM; Re A; Dal Bo M; D'Agaro T; Ferrero S; Bomben R; Gattei V;